TTM Technologies, Inc. — 5.5/10 — $196.95

TTM Technologies is the largest printed circuit board (PCB) manufacturer in North America and the largest supplier of PCBs to the U.S. military. The company manufactures advanced, high-layer-count PCBs used in AI data center infrastructure, defense radar/missile systems, networking equipment, and medical devices. Revenue is concentrated in two secular growth themes: Aerospace & Defense (40% of Q1 2026 revenue) and Data Center & Networking (36%), with the remainder split between Medical/ Industrial (16%) and Automotive (8%). Management targets 15–20% annual revenue growth and doubling earnings from 2025 to 2027 through organic capacity expansion.

Two of three pre-score quality criteria failed — composite capped at 5.5/10.

"Below Quality Bar — Requires Exceptional Catalyst." Raw composite of 6.85 capped at 5.5.

TTM Technologies scores a 5.5/10, capped by the quality gate after failing two of three criteria: no oligopoly position and negative free cash flow. The raw composite of 6.85 reflects genuinely impressive execution — revenue accelerating to +30% YoY, margins expanding 530bps over five years, and management beating guidance five straight quarters. The company is perfectly positioned at the intersection of AI infrastructure and defense spending, with 76% of revenue tied to these two megatrends.

The thesis of "AI demand outpacing street expectations" is well-supported. Book-to-bill of 1.41x (1.65x commercial), CapEx raised 25% to $300–320M, and only 4 analysts covering a $20B company all point to demand visibility that the street hasn't fully modeled. Management has earned credibility through consistent execution.

The "oligopoly" thesis does not hold. TTM has ~20% share in US A&D PCB — the largest player, but in a fragmented market with dozens of qualified competitors. In AI/data center PCBs, Taiwanese and Japanese rivals (Unimicron, Compeq, Tripod) have comparable or larger positions, and hyperscalers actively multi-source. TTM is a price-taker in most commercial segments.

The combination of no structural dominance and negative FCF during a heavy CapEx cycle ($300–320M in FY2026) means this is a momentum story priced for perfection at 54x forward P/E — not a compounder you can hold through a cycle.

Key catalysts and monitoring points:

• Q2 2026 earnings (late July 2026): Guided $930–970M revenue and $0.82–0.88 EPS. A beat here would confirm the demand acceleration thesis and could force analyst upgrades given thin 4-analyst coverage.
• Syracuse ultra-HDI facility (H2 2026): Volume production of DoD-backed ultra-HDI PCBs. Execution here validates the domestic manufacturing premium thesis.
• FCF inflection (H2 2026–2027): As Syracuse CapEx peaks and revenue scales, FCF should recover. Watch for positive FCF quarters — this would remove one quality gate failure.
• Market share evolution: If TTM can demonstrate durable pricing power or share gains above 30% in any segment, the oligopoly gate reassessment becomes warranted.
• Customer concentration: Top 2 customers at 26% of sales (up from 23%). Monitor for further narrowing — a single hyperscaler pullback could create a meaningful revenue gap.
• Earnings doubling target (FY2027): Non-GAAP EPS needs to reach ~$4.92 by FY2027 from $2.46 in FY2025. Street consensus at $5.02 suggests this is achievable.

Watch list — do not own at current levels. At $197 and 54x forward P/E (2x+ PCB peer multiples), the stock prices in flawless execution through 2027 with no margin of safety. The quality gate failures (no oligopoly + no FCF) mean the risk/reward is asymmetrically skewed to the downside at these levels. Revisit if: (1) valuation compresses to 25–30x forward P/E ($90–110 range), (2) FCF turns decisively positive as CapEx cycle peaks, or (3) evidence of genuine pricing power or market share gains above 30% emerges. The underlying business execution is excellent — the issue is the price, not the company.